Effect of ursodeoxycholi acid on liver cirrhosis with hepatitis B

Journal of Central South University (Medical Sciences)

Volumn 35, Issue 2, 2010, Pages 171-175

  Wang, Xiaoyan ^a   Shen, Shourong ^a   Li, Nan ^a   Li, Yu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Liver cirrhosis; Therapeutic effect; Ursodeoxycholi acid

Indexed keywords

ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALKALINE PHOSPHATASE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; URSODEOXYCHOLIC ACID;

EID: 77949854851     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2010.02.014     Document Type: Article

References (13)

1. Mas N, Tasci I, Comert B, et al. Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis [J]. World J Gastroenterol, 2008, 14(7): 1108-1111.
2. Festi D, Montagnani M, Azzaroli F, et al. Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases [J]. Curr Clin Pharmacol, 2007, 2 ( 2 ) . 155-177.
3. Kuiper E M, Hansen B E, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid [J]. Gastroenterology, 2009,136(4) 1281-1287.
4. Copaci I, Micu L, Iliescu L, et al. New therapeutical indications of ursodeoxycholic acid [J]. Rom J Gastroenterol, 2005, 14(3) : 259-266.
5. Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association. The strategy for prevention and therapy of viral hepatitis [J]. Chinese Journal of Hepatology, 2000,8(6) : 324-329.
6. ZHENG Xiaoyu. Guidance principle of clinical study on new drug of traditional Chinese medicine [M]. Beijing : Chinese Medical and Pharmaceutical Science Press,2002.
7. Kitiyakara T, Chapman R W. Chemoprevention and screening in primary sclerosing cholangitis [J]. Postgrad Med J, 2008, 84(991) : 228-237.
8. Crosignani A, Battezzati P M, Invemizzi P, et al. Clinical features and management of primary biliary cirrhosis [J]. World J Gastroenterol, 2008,14(21 ) : 3313-3327.
9. Beuers U. Drug insight : Mechanisms and sites of action of ursodeoxycholic acid in cholestasis [J]. Nat Clin Pract Gastroenterol Hepatol, 2006, 3(6) : 318-328
10. Charatcharoenwitthaya P, Lindor K D. Primary sclerosing cholangitis : diagnosis and management [J]. Curr Gastroenterol Rep, 2006, 8(1) : 75-82.
11. Castro R E, Sola S, Ma X, et al. A distinct microarray gene expression profile in primary rat hepatocytes incubated with ursodeoxycholic acid [J] . J Hepatol, 2005, 42(6) : 897-906.
12. Miyaguchi S, Mori M. Ursodeoxycholic acid ( UDCA ) suppresses liver interleukin 2 mRNA in the cholangitis model [J]. Hepatogastroenterology,2005, 52(62) : 596-602
13. Kikuchi K, Hsu W, Hosoya N, et al. Ursodeoxycholic acid reduces CpG-induced IgM production in patients with primary biliary cirrhosis [J]. Hepatol Res, 2009, 39 ( 5 ) : 448454.